| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CDKL2 |
| Uniprot No | Q92772 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-493aa |
| 氨基酸序列 | MEKYENLGLVGEGSYGMVMKCRNKDTGRIVAIKKFLESDDDKMVKKIAMR EIKLLKQLRHENLVNLLEVCKKKKRWYLVFEFVDHTILDDLELFPNGLDY QVVQKYLFQIINGIGFCHSHNIIHRDIKPENILVSQSGVVKLCDFGFART LAAPGEVYTDYVATRWYRAPELLVGDVKYGKAVDVWAIGCLVTEMFMGEP LFPGDSDIDQLYHIMMCLGNLIPRHQELFNKNPVFAGVRLPEIKEREPLE RRYPKLSEVVIDLAKKCLHIDPDKRPFCAELLHHDFFQMDGFAERFSQEL QLKVQKDARNVSLSKKSQNRKKEKEKDDSLVEERKTLVVQDTNADPKIKD YKLFKIKGSKIDGEKAEKGNRASNASCLHDSRTSHNKIVPSTSLKDCSNV SVDHTRNPSVAIPPLTHNLSAVAPSINSGMGTETIPIQGYRVDEKTKKCS IPFVKPNRHSPSGIYNINVTTLVSGPPLSDDSGADLPQMEHQH |
| 预测分子量 | 81 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CDKL2重组蛋白的3篇代表性文献示例(注：文献为虚拟概括，实际研究需根据具体数据库检索)：
1. **文献名称**：*Structural insights into CDKL2 kinase domain and its regulation by phosphorylation*
**作者**：Li, X., et al.
**摘要**：本研究通过X射线晶体学解析了CDKL2重组蛋白激酶结构域的3D结构，揭示了其ATP结合口袋特征及磷酸化修饰对其激酶活性的调控机制，为靶向药物设计提供结构基础。
2. **文献名称**：*CDKL2 promotes tumor invasion via ERK signaling pathway in colorectal cancer*
**作者**：Wang, Y., et al.
**摘要**：利用重组CDKL2蛋白进行体外功能实验，发现其通过磷酸化下游靶点激活ERK信号通路，促进结直肠癌细胞迁移和侵袭，提示其作为癌症治疗潜在靶点。
3. **文献名称**：*Recombinant CDKL2 expression and interaction with 14-3-3 proteins in neuronal development*
**作者**：Martinez, R., et al.
**摘要**：通过原核系统表达纯化CDKL2重组蛋白，结合Pull-down实验证实其与14-3-3蛋白的相互作用，并发现该互作调控神经元突触可塑性，关联神经发育障碍疾病机制。
---
**提示**：实际文献需通过PubMed/Google Scholar检索关键词“CDKL2 recombinant protein”或“CDKL2 kinase”获取，可重点关注其结构与功能、信号通路及疾病关联研究。
CDKL2 (Cyclin-Dependent Kinase-Like 2) is a serine/threonine protein kinase belonging to the CDKL family, which shares structural homology with mitogen-activated protein (MAP) kinases and cyclin-dependent kinases (CDKs). It is encoded by the CDKL2 gene located on the X chromosome (Xp22.13) and is implicated in regulating cell cycle progression, signal transduction, and neuronal development. While less studied than its paralog CDKL5 (linked to neurodevelopmental disorders), CDKL2 has gained attention for its potential roles in cancer and brain function.
Recombinant CDKL2 protein is produced via genetic engineering, typically using expression systems like Escherichia coli or mammalian cell lines, to ensure proper post-translational modifications and kinase activity. The purified protein retains functional domains, including the kinase domain critical for phosphorylating downstream targets, enabling researchers to study its biochemical properties, substrate specificity, and interaction networks.
Biologically, CDKL2 is associated with pathways such as Wnt/β-catenin and PI3K/AKT, influencing cell proliferation, differentiation, and survival. Dysregulation of CDKL2 has been observed in cancers, including gliomas and breast cancer, where it may act as an oncogene or tumor suppressor depending on context. In the brain, it interacts with cytoskeletal proteins, suggesting roles in synaptic plasticity. Recombinant CDKL2 facilitates drug discovery efforts, serving as a tool for screening kinase inhibitors or elucidating molecular mechanisms in disease models. However, its precise physiological functions and regulatory mechanisms remain partially unresolved, highlighting the need for further research to clarify its therapeutic potential.
×
